• Company Information
  • Product Pipeline
  • Investor Relations
  • Press Room
  • Careers
  • Contact
Specialists are looking for new drugs to address increased resistance today.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs in the areas of infection, cancer and respiratory disease. The Company’s lead product candidate, cethromycin, is a novel once-a-day antibiotic developed for the treatment of respiratory tract infections. The Company has three product candidates that are either in clinical development or approved to begin clinical development, as well as six additional candidates in preclinical development.

Media Fact SheetMedia Fact Sheet

Press Room

Date Title
07/08/08 ‘Doing Drugs’ as seen in University of Notre Dame Magazine
07/03/08 Advanced Life Sciences Added to Russell Microcap Index
06/25/08 Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)

About Cethromycin

Cethromycin, Advanced Life Sciences’ lead product candidate, is a novel once-a-day antibiotic that recently demonstrated positive phase III results for the treatment of community acquired pneumonia (CAP). Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance.

   
 
  • Home
  • Contact
  • Site Map
© 2008 Advanced Life Sciences Inc.   Terms of Use